228 related articles for article (PubMed ID: 32826531)
1. Chondroblastoma Expresses RANKL by RNA In Situ Hybridization and May Respond to Denosumab Therapy.
Suster DI; Kurzawa P; Neyaz A; Jarzembowski JA; Lozano-Calderon S; Raskin K; Schwab J; Choy E; Chebib I; Deshpande V
Am J Surg Pathol; 2020 Dec; 44(12):1581-1590. PubMed ID: 32826531
[TBL] [Abstract][Full Text] [Related]
2. Giant Cell Lesions of the Maxillofacial Skeleton Express RANKL by RNA In Situ Hybridization Regardless of Histologic Pattern.
Stagner AM; Sajed DP; Nielsen GP; Ebb DH; Faquin WC; Chebib I; Rivera MN; Ting DT; Resnick CM; Peacock ZS; Kaban LB; Deshpande V
Am J Surg Pathol; 2019 Jun; 43(6):819-826. PubMed ID: 30998511
[TBL] [Abstract][Full Text] [Related]
3. Receptor-Activator of Nuclear KappaB Ligand Expression as a New Therapeutic Target in Primary Bone Tumors.
Yamagishi T; Kawashima H; Ogose A; Ariizumi T; Sasaki T; Hatano H; Hotta T; Endo N
PLoS One; 2016; 11(5):e0154680. PubMed ID: 27163152
[TBL] [Abstract][Full Text] [Related]
4. Denosumab-treated giant cell tumor of bone. Its histologic spectrum and potential diagnostic pitfalls.
Roitman PD; Jauk F; Farfalli GL; Albergo JI; Aponte-Tinao LA
Hum Pathol; 2017 May; 63():89-97. PubMed ID: 28235628
[TBL] [Abstract][Full Text] [Related]
5. Denosumab-treated Giant Cell Tumor of Bone Exhibits Morphologic Overlap With Malignant Giant Cell Tumor of Bone.
Wojcik J; Rosenberg AE; Bredella MA; Choy E; Hornicek FJ; Nielsen GP; Deshpande V
Am J Surg Pathol; 2016 Jan; 40(1):72-80. PubMed ID: 26414220
[TBL] [Abstract][Full Text] [Related]
6. RANK signalling in bone lesions with osteoclast-like giant cells.
Won KY; Kalil RK; Kim YW; Park YK
Pathology; 2011 Jun; 43(4):318-21. PubMed ID: 21532526
[TBL] [Abstract][Full Text] [Related]
7. Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series.
Girolami I; Mancini I; Simoni A; Baldi GG; Simi L; Campanacci D; Beltrami G; Scoccianti G; D'Arienzo A; Capanna R; Franchi A
J Clin Pathol; 2016 Mar; 69(3):240-7. PubMed ID: 26338802
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemistry for histone H3G34W and H3K36M is highly specific for giant cell tumor of bone and chondroblastoma, respectively, in FNA and core needle biopsy.
Schaefer IM; Fletcher JA; Nielsen GP; Shih AR; Ferrone ML; Hornick JL; Qian X
Cancer Cytopathol; 2018 Aug; 126(8):552-566. PubMed ID: 29757500
[TBL] [Abstract][Full Text] [Related]
9. Pathogenesis of Osteosclerotic Change Following Treatment with an Antibody Against RANKL for Giant Cell Tumour of the Bone.
Rosario M; Takeuchi A; Yamamoto N; Hayashi K; Miwa S; Higuchi T; Abe K; Taniguchi Y; Aiba H; Tanzawa Y; Murakami H; Tsuchiya H
Anticancer Res; 2017 Feb; 37(2):749-754. PubMed ID: 28179326
[TBL] [Abstract][Full Text] [Related]
10. Morphologic evaluation of the effect of denosumab on giant cell tumors of bone and a new grading scheme.
Erdogan KE; DevecI MA; Paydas S; Gonlusen G
Pol J Pathol; 2016; 67(4):392-397. PubMed ID: 28547968
[TBL] [Abstract][Full Text] [Related]
11. RANKL, denosumab, and giant cell tumor of bone.
Thomas DM
Curr Opin Oncol; 2012 Jul; 24(4):397-403. PubMed ID: 22581354
[TBL] [Abstract][Full Text] [Related]
12. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.
Branstetter DG; Nelson SD; Manivel JC; Blay JY; Chawla S; Thomas DM; Jun S; Jacobs I
Clin Cancer Res; 2012 Aug; 18(16):4415-24. PubMed ID: 22711702
[TBL] [Abstract][Full Text] [Related]
13. Receptor activator of NF-kappaB ligand (RANKL) is expressed in chondroblastoma: possible involvement in osteoclastic giant cell recruitment.
Huang L; Cheng YY; Chow LT; Zheng MH; Kumta SM
Mol Pathol; 2003 Apr; 56(2):116-20. PubMed ID: 12665629
[TBL] [Abstract][Full Text] [Related]
14. Mutation Analysis of H3F3A and H3F3B as a Diagnostic Tool for Giant Cell Tumor of Bone and Chondroblastoma.
Cleven AH; Höcker S; Briaire-de Bruijn I; Szuhai K; Cleton-Jansen AM; Bovée JV
Am J Surg Pathol; 2015 Nov; 39(11):1576-83. PubMed ID: 26457357
[TBL] [Abstract][Full Text] [Related]
15. Denosumab Treatment for Giant Cell Tumors, Aneurysmal Bone Cysts, and Fibrous Dysplasia-Risks and Benefits.
Pan KS; Boyce AM
Curr Osteoporos Rep; 2021 Apr; 19(2):141-150. PubMed ID: 33616817
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic value of histone 3 mutations in osteoclast-rich bone tumors.
Nohr E; Lee LH; Cates JM; Perizzolo M; Itani D
Hum Pathol; 2017 Oct; 68():119-127. PubMed ID: 28882701
[TBL] [Abstract][Full Text] [Related]
17. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.
Thomas D; Henshaw R; Skubitz K; Chawla S; Staddon A; Blay JY; Roudier M; Smith J; Ye Z; Sohn W; Dansey R; Jun S
Lancet Oncol; 2010 Mar; 11(3):275-80. PubMed ID: 20149736
[TBL] [Abstract][Full Text] [Related]
18. H3F3 mutation status of giant cell tumors of the bone, chondroblastomas and their mimics: a combined high resolution melting and pyrosequencing approach.
Kervarrec T; Collin C; Larousserie F; Bouvier C; Aubert S; Gomez-Brouchet A; Marie B; Miquelestorena-Standley E; Le Nail LR; Avril P; Christophe Pagès J; de Pinieux G
Mod Pathol; 2017 Mar; 30(3):393-406. PubMed ID: 28059095
[TBL] [Abstract][Full Text] [Related]
19. Targeting receptor-activator of nuclear kappaB ligand in aneurysmal bone cysts: verification of target and therapeutic response.
Pelle DW; Ringler JW; Peacock JD; Kampfschulte K; Scholten DJ; Davis MM; Mitchell DS; Steensma MR
Transl Res; 2014 Aug; 164(2):139-48. PubMed ID: 24726460
[TBL] [Abstract][Full Text] [Related]
20. Denosumab: a new treatment option for giant cell tumor of bone.
Lewin J; Thomas D
Drugs Today (Barc); 2013 Nov; 49(11):693-700. PubMed ID: 24308016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
